Trial Profile
Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs S 18986 (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Servier
- 05 Apr 2017 Status changed from suspended to discontinued.
- 15 Nov 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 15 Nov 2010 Planned end date changed to 1 May 2006 as reported by ClinicalTrials.gov.